Sass Gabriele, Nazik Hasan, Penner John, Shah Hemi, Ansari Shajia Rahman, Clemons Karl V, Groleau Marie-Christine, Dietl Anna-Maria, Visca Paolo, Haas Hubertus, Déziel Eric, Stevens David A
California Institute for Medical Research, San Jose, California, USA.
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
J Bacteriol. 2017 Dec 5;200(1). doi: 10.1128/JB.00345-17. Print 2018 Jan 1.
and are common opportunistic bacterial and fungal pathogens, respectively. They often coexist in airways of immunocompromised patients and individuals with cystic fibrosis, where they form biofilms and cause acute and chronic illnesses. Hence, the interactions between them have long been of interest and it is known that can inhibit We have approached the definition of the inhibitory molecules by studying 24 mutants with various virulence genes deleted for the ability to inhibit biofilms. The ability of cells or their extracellular products produced during planktonic or biofilm growth to affect biofilm metabolism or planktonic growth was studied in agar and liquid assays using conidia or hyphae. Four mutants, the , , , and mutants, were shown to be defective in various assays. This suggested the siderophore pyoverdine as the key inhibitory molecule, although additional quorum sensing-regulated factors likely contribute to the deficiency of the latter two mutants. Studies of pure pyoverdine substantiated these conclusions and included the restoration of inhibition by the pyoverdine deletion mutants. A correlation between the concentration of pyoverdine produced and antifungal activity was also observed in clinical isolates derived from lungs of cystic fibrosis patients. The key inhibitory mechanism of pyoverdine was chelation of iron and denial of iron to Interactions between human pathogens found in the same body locale are of vast interest. These interactions could result in exacerbation or amelioration of diseases. The bacterium affects the growth of the fungus Both pathogens form biofilms that are resistant to therapeutic drugs and host immunity. and biofilms are found , e.g., in the lungs of cystic fibrosis patients. Studying 24 mutants, we identified pyoverdine as the major anti- compound produced by Pyoverdine captures iron from the environment, thus depriving of a nutrient essential for its growth and metabolism. We show how microbes of different kingdoms compete for essential resources. Iron deprivation could be a therapeutic approach to the control of pathogen growth.
[细菌名称1]和[真菌名称1]分别是常见的机会性细菌和真菌病原体。它们经常共存于免疫功能低下患者和囊性纤维化患者的气道中,在那里形成生物膜并导致急性和慢性疾病。因此,它们之间的相互作用长期以来一直备受关注,并且已知[细菌名称1]可以抑制[真菌名称1]。我们通过研究24个缺失各种毒力基因的[细菌名称1]突变体抑制[真菌名称1]生物膜的能力,来确定抑制性分子。在琼脂和液体试验中,使用分生孢子或菌丝研究了[细菌名称1]细胞或其在浮游或生物膜生长过程中产生的细胞外产物影响[真菌名称1]生物膜代谢或浮游[真菌名称1]生长的能力。四个突变体,即[突变体名称1]、[突变体名称2]、[突变体名称3]和[突变体名称4]突变体,在各种试验中表现出缺陷。这表明[细菌名称1]的铁载体绿脓菌素是关键的抑制分子,尽管额外的群体感应调节因子可能导致后两个突变体的缺陷。对纯绿脓菌素的研究证实了这些结论,包括绿脓菌素缺失突变体恢复抑制作用。在源自囊性纤维化患者肺部的临床[细菌名称1]分离株中也观察到绿脓菌素产生浓度与抗真菌活性之间的相关性。绿脓菌素的关键抑制机制是螯合铁并剥夺[真菌名称1]的铁。在同一身体部位发现的人类病原体之间的相互作用备受关注。这些相互作用可能导致疾病的加重或改善。细菌[细菌名称1]影响真菌[真菌名称1]的生长。两种病原体都形成对治疗药物和宿主免疫有抗性的生物膜。[细菌名称1]和[真菌名称1]生物膜例如在囊性纤维化患者的肺部中被发现。通过研究24个[细菌名称1]突变体,我们确定绿脓菌素是[细菌名称1]产生的主要抗[真菌名称1]化合物。绿脓菌素从环境中捕获铁,从而剥夺[真菌名称1]生长和代谢所需的营养物质。我们展示了不同王国的微生物如何竞争必需资源。铁剥夺可能是控制病原体生长的一种治疗方法。